gcmaf2Often the question arises about the molecule known as GcMAF - we hope you find the following information useful:

In 2008-2009, four human studies appeared claiming fantastic results for a groundbreaking new cancer treatment. The studies were conducted Dr. Nabuto Yamamoto, who at the time was a Professor of Biochemistry at Temple University Medical School in Philadelphia. He was assisted by a team of other researchers.

If the results hold up then the new treatment, a natural protein found in a healthy human body, could be one of the most exciting new cancer developments ever seen.

In the first study, Dr. Yamamoto supplied the protein to doctors treating HIV patients resulting in complete eradication of the infection. After seven years follow-up, their blood counts remained normal.

In another study, the Yamamoto team treated 16 non-anemic metastatic breast cancer patients with a single injection of 100 nanograms of GcMAF per week for 22 weeks. 

In the third study, all 16 non-anemic metastatic prostate patients were tumour free after 24 weeks and remained so at seven years follow-up.

In the fourth study, all eight non-anemic metastatic colorectal patients were cancer-free after 48 weeks and remained so at seven years follow-up as confirmed by CT scans.

In short, and astonishing as it sounds, Professor Yamamoto achieved a 100% remission rate in metastatic cancer patients.

The discovery didn't happen overnight. It was the product of years of research at a respected mainstream medical institution.


The pioneering work of Dr Yamamoto

The foundations of GcMAF began in 1979 when Dr. Yamamoto started basic research in molecular biology and immunology. Each insight obtained in one study became the driving force for the design of the next.

These building blocks of knowledge grew until they formed a huge infrastructure that became his basis for a new theory about how cancer occurs and how it could be treated.

The first publication in a peer-reviewed journal on GcMAF appeared in 1994. Dr. Yamamoto and colleagues at Temple University demonstrated that GcMAF activated macrophages. These are vital immune cells that kill pathogens and cancer cells and switch on other aspects of the immune system.

A year later he showed that a defect in the production of GcMAF inside the body contributes to a poorer immune response in AIDS patients. In 1996 he demonstrated that this was also the case in cancer patients.

What is GcMAF and how does it work?

Professor Yamamoto discovered that cancer cells and some viruses, but not normal cells, secrete an enzyme called alpha-N-acetyl-galactosaminidase (Nagalase).

This enzyme is able to block the production of a protein that activates macrophages to attack the cancer cells. He named this Gc-protein-derived Macrophage Activating Factor, GcMAF for short.

Certain immune cells, T and B lymphocytes, make GcMAF from its precursor, vitamin D-transport protein (Gc protein). This protein has three sugars attached to the 420th amino acid along its 458 amino acid chain. The removal of two of these sugars by enzymes produced by the lymphocytes turns Gc protein into GcMAF.

The enzyme released by cancer cells and some viruses, nagalase, removes some sugars from Gc protein, thereby preventing its conversion to GcMAF and rendering the patients’ immune system deficient. The sugar-removing process is called deglycosylation.

Nagalase’s ability to inhibit macrophage activation can be bypassed by using GcMAF. The treatment restores normal immunity and the body is then able to attack tumourcells.

Professor Yamamoto demonstrated that when macrophages are activated by GcMAF their efficacy increases by 30-fold. There is also a 15-fold rise in superoxide ions. These also attack pathogens and cancer cells.

GcMAF is least likely to work in patients who have a large tumour burden and in those whose tumours are well differentiated (i.e. look similar to normal cells). It works best in those with a low tumour load and in poorly differentiated (highly abnormal) cells.

GcMAF can be stopped from working by opiates and steroids or patients lacking sufficient red blood cells.

Dr. Yamamoto’s subjects had undergone conventional therapies to reduce the tumour burden to a very low level. They were also at an early stage of metastasis and had no conditions that could block the protein.

Other anticancer effects of GcMAF

Until 2002 it was believed GcMAF activated only macrophages. Then Professor Yamamoto, together with researchers from Japan, discovered that GcMAF has direct anti-angiogenic effects on endothelial cells. (Angiogenesis is the process whereby cancer tumours form their own network of blood vessels.)

This finding was confirmed the following year by the highly distinguished doctor Judah Folkman and others at Children's Hospital in Boston.

For one factor to both activate the immune system and anti-angiogenesis is remarkable, but the good news doesn't stop there.

In 2010, researchers from the University of Kentucky showed for the first time that GcMAF directly inhibits the migration, proliferation and metastatic potential of human prostate cancer cells. This happened independently of macrophage activation.

And in 2012 the Kentucky discovery was confirmed in breast cancer cells, thanks to the efforts of Marco Ruggiero, a professor of molecular biology, working with a team at the University of Florence, Italy.

But what was more extraordinary, the Italian researchers demonstrated a reversal of breast cancer cells to their neoplastic phenotype. In other words, GcMAF reverted cancer cells back to normal cells.

They also published a study in 2011 demonstrating that GcMAF can counter the potentially carcinogenic effects of cadmium in human breast cancer cells.

About Cytoinnovations

Protein extraction & purification

Our partner laboratory is ISO & GMP registered, and one of the leading protein specialist laboratories in Europe. The protein found in our Vitamin D Transport Protein (VDTP) products is the precursor(natural source) to GcMAF, this means VDTP activates more immune cell types (Lymphocytes, T & B Cells and variants of) before converting to GcMAF in the body and activating the Macrophage immune cell. 

Protein extraction, purification and conversion is a 34 step process that includes full activity and sterility assays which we publish on our website, We kindly ask you to find attached documents

Pricing & efficacy

In 2013, 2.2ml GcMAF sold for 660euros, the strength was only 440ng 

In 2014 we founded Cytoinnovations Ltd with the expressed goals of producing registered, effective and affordable products that support the immune system.

Since then we have been able to reduce the price whilst at the same time increasing the strengths and supporting many research initiatives at the same time.

Cytoinnovations Ltd was formed in the United Kingdom in 2014 with the expressed goals of producing registered, effective and affordable products that support the immune system.

Our laboratory tests showed that VDTP is dose dependant when used against cancer cells. This means that more is better. That is why we have raised the potency of our products from 220ng to 50,000ng which is more than 3x stronger than any other currently available product.

We sell 15ml of VDTP at 2,500ng strength for 110 euros, 15,000ng for 400 euros & 50,000ng for 850 euros.

Full product specification and prices can be viewed on our website here:


Our Autism research initiatives

Since 2014 we have supported 1000’s of families with autism and have some of the results published here:



Supporting clinics that cure Cancer

Although our main focus has always been on the autism community, there is ample evidence to show that GcMAF/VDTP is an effective intervention for the treatment of cancer. So we produce high strength suspensions for injections GcMAF for research purposes and supply only to selected doctors and cancer clinics. Again these products have been tested to the highest pharmaceutical standards.

GcMAF has been thoroughly researched over the last 30 years and hundreds of research papers, published in respected journals testify the the immunological and therapeutic effects of this protein. Most of these research papers are freely available on the internet but we have included a few papers below. 

Trevor Banks

Managing Director

Cytoinnovations Ltd


This email address is being protected from spambots. You need JavaScript enabled to view it.

Share This Article

Shopping Cart

No

Select Currency

Go to top
GcMAF.LA Lista de Correo, Mailing List

No compartiremos su correo electrónico con un tercero.
We will not share your email with a third party.